Archives of Obesity and Metabolism (비만대사연구학술지)

The Study of Obesity and Metabolic Syndrome, KAFM (대한가정의학회 비만대사증후군연구회)
권호 표지
DOI QR코드

DOI QR Code

Morbidly Obese Patients Treated Obesity and Metabolic Diseases Using Naltrexone/Bupropion Extended Release and Other Drugs of Various Mechanisms

날트렉손/부프로피온 복합제 및 여러 기전의 약물을 이용하여 비만과 동반 대사질환을 치료한 고도비만환자

  • Cho, Soo Hyun (Department of Family Medicine, College of Medicine, Chung-Ang University Hospital)
  • 조수현 (중앙대학교병원 가정의학과)
  • Received : 2022.10.18
  • Accepted : 2022.12.06
  • Published : 2022.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Obesity increases the risk of developing metabolic diseases such as hypertension, type 2 diabetes, hyperlipidemia, and cardiovascular diseases, as well as some cancers. To prevent the occurrence of these diseases and death, it is essential to manage obesity. Though there are several treatments for obesity, lifestyle interventions, such as diet and exercise, and drug therapy are most widely used in clinical practice. Among the anti-obesity drugs available, the weight loss effect of naltrexone/bupropion has been well-proven. We present a case study in which naltrexone/bupropion, a glucagon-like peptide-1 agonist, and a sodium-glucose transporter 2 inhibitor showed significant weight loss and improved metabolic parameters. Additionally, the management of type 2 diabetes and hypertension, which are common diseases in patients with obesity, was also included.

Keywords

References

  1. Brown CD, Higgins M, Donato KA, et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 2000;8:605-19. https://doi.org/10.1038/oby.2000.79
  2. Larsson B, Bjorntorp P, Tibblin G. The health consequences of moderate obesity. Int J Obes 1981;5:97-116.
  3. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell 2001;104:531-43. https://doi.org/10.1016/S0092-8674(01)00240-9
  4. Walker SP, Rimm EB, Ascherio A, Kawachi I, Stampfer MJ, Willett WC. Body size and fat distribution as predictors of stroke among US men. Am J Epidemiol 1996;144:1143-50. https://doi.org/10.1093/oxfordjournals.aje.a008892
  5. Stampfer MJ, Maclure KM, Colditz GA, Manson JE, Willett WC. Risk of symptomatic gallstones in women with severe obesity. Am J Clin Nutr 1992;55:652-8. https://doi.org/10.1093/ajcn/55.3.652
  6. Cicuttini FM, Baker JR, Spector TD. The association of obesity with osteoarthritis of the hand and knee in women: a twin study. J Rheumatol 1996;23:1221-6.
  7. Millman RP, Carlisle CC, McGarvey ST, Eveloff SE, Levinson PD. Body fat distribution and sleep apnea severity in women. Chest 1995;107:362-6. https://doi.org/10.1378/chest.107.2.362
  8. Bostick RM, Potter JD, Kushi LH, et al. Sugar, meat, and fat intake, and non-dietary risk factors for colon cancer incidence in Iowa women (United States). Cancer Causes Control 1994;5:38-52. https://doi.org/10.1007/BF01830725
  9. The Study of Obesity and Metabolic Syndrome. Useful knowledge of obesity treatment to know. Daejeon: The Study of Obesity and Metabolic Syndrome; 2021.
  10. Frias JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2016;4:1004-16. Erratum in: Lancet Diabetes Endocrinol 2017;5:e8. https://doi.org/10.1016/S2213-8587(16)30267-4
  11. Ludvik B, Frias JP, Tinahones FJ, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2018;6:370-81. Erratum in: Lancet Diabetes Endocrinol 2018;6:e5. https://doi.org/10.1016/S2213-8587(18)30023-8
  12. Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUS-TAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2019;7:356-67. Erratum in: Lancet Diabetes Endocrinol 2019;7:e5. Erratum in: Lancet Diabetes Endocrinol 2019;7:e20. Erratum in: Lancet Diabetes Endocrinol 2019;7:e22. https://doi.org/10.1016/S2213-8587(19)30066-X
  13. Blonde L, Belousova L, Fainberg U, et al. Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2020;22:929-37. https://doi.org/10.1111/dom.13978
  14. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24:412-24. https://doi.org/10.1016/j.eurpsy.2009.01.005
  15. Afzal M, Siddiqi N, Ahmad B, et al. Prevalence of overweight and obesity in people with severe mental illness: systematic review and meta-analysis. Front Endocrinol (Lausanne) 2021;12:769309. https://doi.org/10.3389/fendo.2021.769309
  16. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010;67:220-9. https://doi.org/10.1001/archgenpsychiatry.2010.2
  17. Yang YS, Han BD, Han K, Jung JH, Son JW. Obesity fact sheet in Korea, 2021: trends in obesity prevalence and obesity-related comorbidity incidence stratified by age from 2009 to 2019. J Obes Metab Syndr 2022;31:169-77. https://doi.org/10.7570/jomes22024
  18. Park ES, Lee EH. Obesity and related-factors in patients with chronic mental illness registered to community mental health welfare centers. J Korean Acad Community Health Nurs 2018;29:76-86. https://doi.org/10.12799/jkachn.2018.29.1.76
  19. Pi-Sunyer X, Apovian CM, McElroy SL, Dunayevich E, Acevedo LM, Greenway FL. Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis. Int J Obes (Lond) 2019;43:2085-94. https://doi.org/10.1038/s41366-018-0302-z
  20. Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA 2016;315:990-1004. https://doi.org/10.1001/jama.2016.1558
  21. McIntyre RS, Paron E, Burrows M, et al. Psychiatric safety and weight loss efficacy of naltrexone/bupropion as add-on to antidepressant therapy in patients with obesity or overweight. J Affect Disord 2021;289:167-76. https://doi.org/10.1016/j.jad.2021.04.017